Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Genetic Technologies's operating assets for the quarter that ended in Jun. 2024 was €3.22 Mil. Genetic Technologies's operating liabilities for the quarter that ended in Jun. 2024 was €2.18 Mil. Genetic Technologies's Total Assets for the quarter that ended in Dec. 2023 was €5.23 Mil. Therefore, Genetic Technologies's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.20.
Genetic Technologies Scaled Net Operating Assets Related Terms
Genetic Technologies Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Genetic Technologies's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Technologies Scaled Net Operating Assets Chart
STU:DU8 vs LDDD, NOTV, ATLN: Scaled Net Operating Assets Comparison
For the Diagnostics & Research subindustry, Genetic Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Technologies Scaled Net Operating Assets vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Genetic Technologies's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.20 mean?
Genetic Technologies (STU:DU8) has a Scaled Net Operating Assets of 0.20 as of Jun. 2024. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Scaled Net Operating Assets too high?
Genetic Technologies' current Scaled Net Operating Assets is 0.20.
How does Genetic Technologies' Scaled Net Operating Assets compare to LDDD and NOTV?
Genetic Technologies' Scaled Net Operating Assets of 0.20 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Diagnostics & Research company?
A good Scaled Net Operating Assets depends on the Medical Diagnostics & Research industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Scaled Net Operating Assets is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (STU:DU8) has a current Scaled Net Operating Assets of 0.20. The current Scaled Net Operating Assets is 0.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Genetic Technologies (STU:DU8), the current Scaled Net Operating Assets is 0.20 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:DU8 has been successfully added to your 
